Alliança (AALR3) reported challenging Q1 2024 results. The diagnostic medicine company, formerly known as Alliar, faced an adjusted net loss of R$ 70.8 million ($13.75 million). This represents a 119.8% increase from the same period last year. The company attributed this loss to debt restructuring strategies and capital structure improvements, including significant debt liquidation. Additionally, […]